Theraclion: New Echotherapy for Varicose Veins Partnership With Parisian Region Hospital Wound Center Announced
29 September 2022 - 7:08PM
Business Wire
Regulatory News:
THERACLION (ISIN: FR0010120402; Mnemo: ALTHE) (Paris:ALTHE),
an innovative company developing a scalable robotic platform for
non-invasive ultrasound therapy, is announcing a new
partnership with Victor Dupouy Hospital Centre in Argenteuil (95),
in the Parisian region, on echotherapy for varicose veins.
Argenteuil Hospital has just invested in the SONOVEIN® robotic
platform, for the non-invasive treatment of varicose veins. Based
on High Intensity Focused Ultrasound (HIFU) technology, the
cutting-edge equipment has convinced the Vascular Surgery
Department of the Argenteuil Hospital, a national reference in the
treatment of wounds and scarring in France.
‘It is a technology that will enable us to offer patients a
non-invasive treatment, without anaesthesia, particularly for
complex cases of recurrence or for elderly patients. This is
planned during a preliminary consultation, and generally requires a
single session,’ explains Dr Mahine Kashi, a vascular surgeon at
the Argenteuil Hospital.
‘This is our first public hospital installation in Europe and
first wound care centre, where SONOVEIN® will be used to accelerate
the ulcer healing process. The multi-disciplinary care team in
Argenteuil now has a state-of-the-art, non-invasive solution for
patients, particularly those usually associated with massive
healthcare costs. We are delighted to have found in Argenteuil a
unique team to pioneer echotherapy for unmet medical needs in
chronic venous insufficiency’, said David Caumartin, general
director at Theraclion.
The Argenteuil Hospital Centre also brings new hope to patients
suffering from venous ulcers, the most advanced stage of the
disease. Often elderly and suffering from multiple illnesses, they
cannot get operated on. Echotherapy thus offers them an alternative
from other treatments, involving lifelong venous restraint, usually
costly and difficult to monitor.
In France, 20 to 35%1 of the population suffer from superficial
venous insufficiency, i.e. 1 in 3 people. This ‘heavy’ legs
sensation is accentuated by a sedentary lifestyle and heat and can
develop into varicose veins. In addition to the significant impact
of pain on patients’ quality of life and the aesthetic damage of
varicose veins, untreated venous insufficiency can develop into
skin complications such as varicose eczema or venous ulcers.
Consequences that can be avoided through early medical care.
About Theraclion
At Theraclion we believe that surgery, as we know it, is
outdated. It converts optimistic patients into anxious individuals,
brilliant doctors into exhausted system executors and stretches
healthcare systems to the limit. We have disrupted this convention
by creating extracorporeal treatment platforms. We replace surgery
with a robotic treatment from outside the body using High Intensity
Focused Ultrasound (HIFU). Our leading edge echotherapy platforms
are currently CE marked in non-invasive treatment of varicose veins
with SONOVEIN® and of breast fibroadenomas and thyroid nodules with
Echopulse®.
Located in Malakoff, near Paris, our employees live and breathe
innovation by extensive clinical research and harness artificial
intelligence. The market of varicose veins treatment alone requires
around 5 million procedures annually. It is a dynamic market in
which we change paradigms by making non-invasive echotherapy the
new standard.
For more information, please visit
www.theraclion.com and our patient website
www.echotherapy.com.
Theraclion is listed on Euronext Growth Paris Eligible for the
PEA-PME scheme Mnemonic: ALTHE - ISIN code: FR0010120402 LEI:
9695007X7HA7A1GCYD29
1 HAS 2008 report:
https://www.has-sante.fr/upload/docs/application/pdf/2008-07/rapport_radiofrequence_saphene_vd.pdf
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220929005799/en/
Theraclion David AUREGAN Chief Operating Officer
david.auregan@theraclion.com
Theraclion (EU:ALTHE)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Theraclion (EU:ALTHE)
Historical Stock Chart
Von Apr 2023 bis Apr 2024